Nattokinase Long-Term Safety: What the Data Actually Covers – and What It Doesn’t

Nattokinase safety over the long term is the question that separates a supplement people try for a month from one they take every day for a decade. It is also the question the published research has the least direct answer to, because the trials that put nattokinase on the map were designed to measure blood pressure and clotting markers over weeks — not to find out what happens to a capsule user after five years. This article sets out exactly what the long-term evidence covers, where it stops, and which questions to put to a clinician before you commit to daily use for years.

Two things to say up front, because they colour everything below. Nothing here is medical advice, and nothing here promises that nattokinase will prevent a heart attack, a stroke, a blood clot, or any other condition. Nattokinase is a fibrinolytic enzyme — it acts on fibrin, the protein that forms a clot — which means it works on the same system that stops you bleeding out. Any product that claims a nattokinase capsule dissolves clots “safely” is selling a promise the evidence does not support. What follows is a map of the evidence: how long the studies actually ran, what they measured, what they found, and — just as importantly — which parts of “taking it every day for years” nobody has actually studied.

How long is "long-term" in the nattokinase evidence base?

Start with the shortest possible answer: in the randomised evidence, “long-term” usually means about two months. The most recent systematic review and meta-analysis of nattokinase trials pooled six randomised controlled studies with 546 participants for quantitative analysis, and reported their follow-up durations plainly — five of the studies evaluated participants at eight weeks, one ran for six months, and a single study carried on for three years.¹ The daily doses across those trials ranged from 1,200 to 8,000 fibrinolytic units (FU).

That is the entire randomised safety dataset: a median follow-up of roughly two months, with one three-year outlier and one six-month study. If you have read a page claiming nattokinase is “proven safe for long-term use”, it is almost certainly pointing at those eight-week trials and at observational data from a completely different population — Japanese people who eat fermented soy, not people who swallow a standardised capsule. Both kinds of evidence are worth having. They are not interchangeable, and the difference is the single most useful thing to understand about this question.

There is a second, longer layer of evidence that does not involve capsules at all. Japanese population cohorts have followed habitual natto eaters for 10 to 20 years, and a 2025 systematic review of 52 prospective cohort studies pulled together 632,714 participants with follow-up durations ranging from 10 to more than 20 years.² That is genuine long-term data on fermented soybean. It is also observational data about a food, and it cannot be read across to a capsule product.

What the longest capsule study actually followed

The one study that genuinely extended capsule follow-up past a year is a 2022 clinical study in 1,062 participants, published in Frontiers in Cardiovascular Medicine. It followed people taking 10,800 FU of nattokinase daily for 12 months and reported no noticeable adverse effects associated with the nattokinase itself.³ That is the best capsule-specific long-horizon dataset that exists, and it is worth reading closely rather than skimming.

Three features of it matter. First, it was a single-arm clinical study, not a randomised placebo-controlled trial, so participants were not blinded and there was no comparison group to benchmark side effects against. Second, the effective dose in that study was 10,800 FU per day — roughly five times the 2,000 FU per capsule that is the common marketed daily dose, and five times the dose the authors themselves describe as challenging the recommended 2,000 FU per day.³ The same study found nattokinase ineffective for lipid lowering at 3,600 FU per day. Third, the trial was run by a commercial nattokinase manufacturer, which does not invalidate it but does mean the adverse-event collection was done by an interested party.

So read it this way: it is reassuring evidence that people taking a high dose of nattokinase for a year generally tolerated it, and it is not evidence that a decade of capsule use is well studied. Twelve months is not the same as twelve years, and no study anywhere has followed capsule users for twelve years.

What the Japanese natto data covers — and what it does not

The long-duration evidence that does exist comes from Japan, and it is worth being precise about what it measured. The Japan Public Health Center-based Prospective Study followed 92,915 adults aged 45 to 74 for about 15 years, and found that people in the highest fifth of fermented soy intake (natto and miso) had lower all-cause mortality than those in the lowest fifth — hazard ratios of 0.90 in men and 0.89 in women — and that natto intake specifically was inversely associated with cardiovascular-disease-related mortality in both sexes.⁴ The authors were careful to note that total soy intake showed no such association, and that residual confounding could be attenuating even the fermented-soy signal.

A 2025 systematic review of 52 prospective cohorts reached a similar conclusion in broader terms: fermented food consumption, including fermented soy, was associated with a modest inverse association with all-cause and cardiovascular mortality, while the authors stressed that the current evidence remains insufficient to support formal health claims.² That word “modest” is doing a lot of work, and so is “insufficient”.

Here is what this evidence cannot tell you, and the gap is larger than it first appears:

• It is about food, not capsules. A bowl of natto delivers a variable, unquantified amount of nattokinase activity alongside vitamin K2, fibre and polyamines. A capsule delivers a stated FU number and nothing else. The exposure is not the same.
• It is observational, not randomised. People who eat natto daily differ systematically from people who do not — in diet, activity, alcohol, income, and access to healthcare. The mortality differences may reflect the whole package rather than the enzyme.
• It contains no capsule users at all. Nobody in these cohorts was taking a 2,000 FU capsule every morning for a decade, so there is no way to ask what would happen to them.
• It is a Japanese population. Baseline dietary habits, fermented-food culture, and the genetic and microbiome background of the cohorts are not the same as the background of a Malaysian or Singaporean adult buying a supplement online.

This is not an argument against fermented soy. It is an argument for not letting a cohort study about a breakfast food quietly stand in for a safety certificate for a concentrated enzyme product.

What the short-term safety data does say

The reassuring half of the picture is real, and it is not nothing. Across the pooled randomised trials, no notable adverse events attributable to nattokinase were reported, and the review authors concluded that nattokinase appeared to be a safe agent with a low haemorrhagic risk and no reported toxicologic concerns.¹ They also noted that the reported safety margin for haemorrhagic effects was roughly three times that of tissue plasminogen activators, that daily nattokinase at 10 mg per kilogram of body weight over 28 days was well tolerated in human volunteers, and that no adverse effects were seen in mice at doses thousands of times the recommended human dose.¹

The individual trials behind that summary are short and modest in size. The 2008 Korean randomised controlled trial enrolled 86 adults with pre-hypertension or stage 1 hypertension and gave them 2,000 FU nattokinase or a placebo for eight weeks, with 73 completing the protocol; systolic blood pressure fell by a net 5.55 mmHg against placebo.⁵ The 2016 North American multicentre trial enrolled 79 people and followed them for the same eight weeks, reporting reductions in systolic and diastolic blood pressure on 100 mg of nattokinase per day.⁶ Both were well conducted for what they were. Neither was designed to answer “what happens after five years”, and neither was powered to detect rare harms.

Nor should the reassuring picture be read as a blank cheque. The same meta-analysis that found no notable adverse events also flagged a small, contradictory set of case reports touching allergic and bleeding risks, and its authors recommended that patients taking nattokinase be monitored for coagulation profile, clinical condition, renal function, diet and weight.¹ A separate review of nattokinase as an oral antithrombotic agent sets out the same interaction concern from the pharmacology side.⁷ That is a narrow, largely theoretical safety margin for anyone on an anticoagulant or antiplatelet drug — and a wide-open question for the older adults most likely to be taking cardiovascular supplements.

The questions long-term data has not answered

Here is the honest list of what nobody has studied, and every item on it is a reason to involve a clinician rather than a forum post.

• Multi-year capsule use. There is no randomised or observational cohort following nattokinase capsule users across a span of years. Twelve months is the longest capsule follow-up that exists.
• Older adults on blood thinners. The trial populations were overwhelmingly middle-aged adults with elevated blood pressure, not the over-70s on warfarin, apixaban, aspirin, clopidogrel, or a combination. That is precisely the group where fibrinolytic activity and antiplatelet effect could compound.
• Pregnancy and breastfeeding. Essentially absent from the published dataset.
• Perioperative use. The stop-before-surgery window is a matter of local anaesthetic protocol, not of trial evidence, because long-term nattokinase users have not been studied as a surgical population.
• Kidney and liver impairment. The meta-analysis explicitly asks for monitoring of renal function, which tells you the question is open rather than settled.
• Batch-to-batch consistency over time. Activity is stated in FU, not milligrams, and the enzyme activity of a fermentation batch varies. What a 2024 label states is not automatically what a 2029 label will state.

How to read a "long-term safe" claim on a label

Long-term safety claims on supplement packaging are marketing language far more often than they are findings. Six things to check on any nattokinase product before you take it daily for years:

• Is the activity stated in FU, and is there a third-party assay behind it? A bare number on the box is worth much less than a published certificate of analysis for that specific batch.
• Is the ingredient a named, standardised preparation? NSK-SD is the commonly referenced standardised fermented soybean extract, and a manufacturer-published comprehensive scientific review of that ingredient is openly available.⁸ A generic “nattokinase” on an ingredient panel tells you less about the enzyme you are getting than about the manufacturer’s sourcing.
• Does the product contain vitamin K2? Many fermented soybean preparations carry vitamin K2 along with the enzyme, and vitamin K2 interacts with warfarin. If you take an anticoagulant, this single line on the label matters more than any marketing claim on the front.
• Is there a printed lot or batch number, and a tamper-evident seal? A product with no traceable batch is a product whose activity you cannot verify and whose problem you cannot trace.
• Is the manufacturer named on the label, with a physical address? An unlisted seller with no manufacturer is a supply-chain question, not a supplement question.
• Is the clinical claim scoped to something specific? “Clinically studied at 2,000 FU for 8 weeks” is a scoped, checkable claim. “Supports cardiovascular health” is not.

Note what this list deliberately does not do: it does not name a certified laboratory, a trusted seller or a price point, and it does not assert that any specific listing you have seen is counterfeit. It gives you questions you can answer yourself from the label in your hand.

What to ask a clinician before committing to daily use for years

Because the long-term evidence is thin by construction, the reasonable use of a doctor here is to substitute for the missing data rather than to rubber-stamp the decision. A productive appointment covers four things:

• Your own bleeding and clotting risk. If you take an anticoagulant or antiplatelet drug, if you have a bleeding disorder, if you have an aneurysm, or if you have had an ulcer or GI bleed in the past, the answer may be a clear no, and that is a good outcome of the conversation.
• Whether your medication list makes the enzyme additive. Give the clinician the full list, including anything bought without a prescription, and ask specifically about the fibrinolytic activity overlapping with your anticoagulant or antiplatelet therapy.
• Whether your kidney and liver function are suitable. This is a standard part of any long-term supplement decision and is precisely the parameter the research literature flags as needing monitoring.
• What to watch for and when to stop. Agree the specific signs — unusual bruising, nosebleeds that will not stop, bleeding gums, blood in urine or stool, a headache unlike your usual one — and the plan if they appear. Decide the review date now, rather than deciding in year three whether to continue.

One practical point worth making at that appointment: the honest question is not “is nattokinase safe?” but “is nattokinase safe for me, at this dose, alongside these medicines, and for this many years?” The published evidence can tell you about the first, third and fifth of those. It cannot tell you about you.

References

1. Li X, Long J, Gao Q, Pan M, Wang J, Yang F, Zhang Y. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine. 2023;24(8):234. doi:10.31083/j.rcm2408234 — https://www.imrpress.com/journal/RCM/24/8/10.31083/j.rcm2408234
2. A systematic review of prospective evidence linking non-alcoholic fermented food consumption with lower mortality risk. Frontiers in Nutrition. 2025 — https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1657100/full
3. Chen H, Zheng Q, Zhang F, et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine. 2022;9:964977. doi:10.3389/fcvm.2022.964977 — https://pmc.ncbi.nlm.nih.gov/articles/PMC9441630/
4. Katagiri R, Sawada N, Goto A, Yamaji T, Iwasaki M, Noda M, Iso H, Tsugane S. Association of soy and fermented soy product intake with total and cause specific mortality: prospective cohort study. BMJ. 2020;368:m34 — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190045/
5. Kim J, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research. 2008;31(8):1583-1588 — https://www.nature.com/articles/hr2008203
6. Jensen GS, Lenninger M, Ero MP, Benson KF. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrated Blood Pressure Control. 2016;9:95-104 — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066864/
7. Weng Y, Yao J, Sparks S, et al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. International Journal of Molecular Sciences. 2017;18(3):523 — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372539/
8. Japan Bio Science Laboratory Co, Ltd. A Comprehensive Scientific Review of Nattokinase (NSK-SD). Osaka: JBSL. — https://www.lv-pharm.rs/wp-content/uploads/2018/01/A-Comprehensive-Scientific-Review-of-Nattokinase.pdf